


I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit: July 2, 2001

Nicholas J. Seay  
Nicholas J. Seay



TECH CENTER 1600/2900

JUL 3 2001

RECEIVED

#1113  
Dmt  
7-16-01

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ronald T. Raines

Date: \_\_\_\_\_, 2001

Serial No.: 09/234,028

Group Art Unit: 1652

Filed: 01/20/99

Examiner: R. Hutson

Title: OXIDATION-RESISTANT  
RIBONUCLEASE INHIBITOR

File No.: 960296.95360

AMENDMENT

Commissioner For Patents  
Washington DC 20231

Dear Sir:

In response to an Office Action dated January 2, 2001 in the file of the above-identified application, please amend the application as follows:

In the Specification:

Please insert the following new paragraph for the paragraph which previously appeared in the specification starting on page 5, line 31 and extending onto page 6, line 7.

RECEIVED  
JUL 12 2001  
TC 1700

RECEIVED  
JUL 12 2001  
TC 1700 MAIL ROOM

B1  
An illustration of the three dimensional structure of the human ribonuclease inhibitor is illustrated in Fig. 1. The sequence of the ribonuclease inhibitor can be found in Lee et al. Biochemistry 27:8545-8553 (1988), the disclosure of which is hereby incorporated by reference. From both Figure 1 and the sequence of the protein, it can be readily seen that some of the cysteine residues are located adjacent to each other. The amino acid residues at

QBMAD\308226.1

-1-

07/10/2001 WABRHAH1 00000070 170055 09234028

01 FC:202 40.00 CH